PGE2 contributes to TGF-β induced T regulatory cell function in human non-small cell lung cancer

American Journal of Translational Research

Volumn 2, Issue 4, 2010, Pages 356-367

  Baratelli, Felicita ^a   Lee, Jay M ^a   Hazra, Saswati ^a   Lin, Ying ^a   Walser, Tonya C ^a   Schaue, Dorthe ^a   Pak, Peter S ^a   Elashoff, David ^a   Reckamp, Karen ^b   Zhang, Ling ^a   Fishbein, Michael C ^a   Sharma, Sherven ^a,c   Dubinett, Steven M ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Departments of Hematology and Medical Oncology   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

CD4+ T cells; Non small cell lung cancer; PGE2; T regulatory cells; TGF

Indexed keywords

CD4 ANTIGEN; CYCLOOXYGENASE 2; HLA DR ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; PROSTAGLANDIN E2; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; CANCER PATIENT; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MALE; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TISSUE SECTION;

EID: 77957330204     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Dubinett S, Sharma S, Huang M, Mao JT, Batra R. Cancer and Immune Dysfunction. In: Finke J, Bukowski R editors. Immunotherapy at the Crossroads: How tumors evade immunity and what can be done. Totowa, NJ: Human Press Inc.; 2004, p 335-350.
3. Baecher-Allan C and Anderson DE. Regulatory cells and human cancer. Sem Cancer Biol 2006; 16: 98-105.
4. Liu VC, Wong LY, Jang T, Shah AH, Park I, Yang X, Zhang Q, Lonning S, Teicher BA, Lee C. Tumor evasion of the immune system by converting CD4+CD25-T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-β. J Immunol 2007; 178: 2883-2892.
5. Shevach EM. Certified professionals: CD4+C25+ suppressor T cells. J. Exp. Med 2001; 193: F41-46.
6. Shevach EM. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009; 30: 636-45.
7. Jonuleit H and Schmitt E. The regulatory T cell family: distinct subsets and their interrelations. J Immunol 2003; 171: 6323-6327.
8. Woo E Y, Chu C S, Goletz T J, Schlienger K, Yeh H, Koukos G, Rubin SC, Kaiser LR, June CH. Regulatory CD4+CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late- stage ovarian cancer. Cancer Res 2001; 61: 4766-4772.
9. Woo E Y, Chu C S, Goletz, T J, Schlienger K, Carrol RG, Riley JL, Kaiser LR, June CH. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002; 168: 4272-4276.
10. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Canc Res 2003; 9: 606-612.
11. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002; 169: 2756-2761.
12. Marshall NA, Christie LE, Munro LR, Culligan DJ, Johnston PW, Barker RN, Vickers MA. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004; 103: 1755-1762.
13. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Edvemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-949.
14. Viguier M, Lemaitre F, Verola O, Cho MS, Gorochov G, Dubetret L, Bachelez H, Kourilsky P, Ferradini L. Foxp3 expressing CD4+CD25 high regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol. 2004; 173: 1444-1453.
15. Petersen RP, Campa MJ, Sperlazza J, Conlon D, Joshi M-B, Harpole DH Jr, Patz EF Jr. Tumor infiltrating FOXP3+ regulatory T cells are associated with recurrence in pathologic stage I NSCLC. Cancer 2006; 107: 2866-2872.
16. Lizee G, Radvanyi LG, Overwijk WW, Hwu P. Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. Clin Cancer Res 2006; 12: 4794-4803.
17. Randolph A and Fathman CG. CD4+CD25+ regulatory T cells and their therapeutic potential. Ann Rev Med 2006; 57: 1.1-1.22.
18. Fantini MC, Becker C, Monteleone G, Pallone F, Galle P R, Neurath MF. Cutting Edge: TGF-β induces a regulatory phenotype in CD4+CD25- T cells through foxp3 induction and downregulation of Smad7. J Immunol 2004; 172: 5149-5153.
19. Pyzik M and Piccirillo CA. TGF-beta1 modulates Foxp3 expression and regulatory activity in distinct CD4+ T cell subsets. J Leuk Biol 2007; 82: 335-346.
20. Li MO, Wan YY, Sanjabi S, Robertson A-KL, Flavell RA. TGF-β regulation of immune responses. Ann Rev Immun 2005; 24: 4.1-4.48.
21. Sheng H, Shao J, Dixon DA, Williams CS, Prescott SM, DuBois RN, Beauchamp RD. Transforming growth factor-beta1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA. J Biol Chem 2000; 275: 6628-35.
22. Liu M, Yang SC, Sharma S, Luo J, Cui X, Peebles KA, Huang M, Sato M, Ramirez RD, Shay JW, Minna JD, Dubinett SM. EGFR Signaling is Required for TGF-beta1 Mediated COX-2 Induction in Human Bronchial Epithelial Cells. Am J Respir Cell Mol Biol 2007; 37: 578-588.
23. Roman CD, Morrow J, Whitehead R, Beauchamp RD. Induction of cyclooxygenase-2 and invasiveness by transforming growth factor-beta (1) in immortalized mouse colonocytes expressing oncogenic Ras. J Gastrointest Surg 2002; 6: 304-9.
24. Takizawa H, Tanaka M, Takami K, Ohtoshi T, Ito K, Satoh M, Okada Y, Yamasawa F, Nakahara K, Umeda A. Increased expression of transforming growth factor-beta1 in small airway epithelium from tobacco smokers and patients with chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med 2001; 163: 1476-83.
25. Barthelemy-Brichant N, David JL, Bosquee L, Bury T, Seidel L, Albert A, Bartsch P, Baugnet Mahieu L, Deneufbourg JM. Increased TGF-β1 plasma level in patients with lung cancer: potential mechanisms. Eur J Clin Invest 2002; 32: 193-198.
26. Kong FM, Washington MK, Jirtle RL, Anscher MS. Plasma transforming growth factor-b1 reflects disease status in patients with lung cancer after radiotherapy: a possible tumor marker. Lung Cancer 1996; 16: 47-59.
27. Anumanthan G, Halder SK, Osada H, Takahashi T, Massion PP, Carbone DP, Datta PK. Restoration of TGF-β signaling reduces tumorigenicity in human lung cancer. Br J Cancer 2005; 93: 1157-67.
28. Neil JR, Johnson KM, Nemenoff RA, Schieman WP. COX-2 inactivates Smad signaling and enhances EMT-stimulated by TGF-beta through a PGE2-dependent mechanism. Carcinogenesisis 2008; 29: 2227-35.
29. Baratelli F, Ying L, Zhu L, Yang SC, Heuze-Vourc'h N, Reckamp K, Zeng G, Sharma S, Dubinett SM. PGE2 modulates CD25+ and CD25- CD4+ T regulatory cell function through induction of FOXP3 expression. J Immunol 2005; 175: 1483-1490.
30. Sharma S, Yang SC, Zhu L, Reckamp K, Gardner B, Baratelli F, Huang M, Batra RJ, Dubinett SM. Tumor COX-2/PGE2 dependent promotion of FOXP3 expression and CD4+CD25+ T Regulatory cell activities in lung cancer. Cancer Res 2005; 65: 5211-5220.
31. Létourneau S, Krieg C, Pantaleo G, Boyman O. J Allergy Clin Immunol IL-2 and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets. J Allergy Clin Immunol. 2009; 123: 758-62.
32. Rochman Y, Spolski R, Leonard WJ. New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol. 2009; 9: 480-90.
33. Dubinett SM, Sharma S, Huang M, Dohadwala M, Pold M, Mao J. Cyclooxygenase-2 in lung cancer. In: COX-2. AJ Dannenberg and RN Dubois eds. Karger, Basel, 2003;p138-162.
34. Baecher-Allan C, Wolf E, Hafler DA. MHC class II expression identifies functionally distinct human regulatory T cells. J Immunol 2006; 176: 4622-4631.
35. Ziegler SF. FOXP3 of mice and men. Annu Rev Immunol 2006; 24: 209-226.
36. Gavin MA, Rasmussen JP, Fontenot JD, Vasta V, Manganiello VC, Beavo JA, Rudensky AY. FOXP3- dependent programme of regulatory T cell differentiation. Nature 2007; 445: 771-775.
37. Gambineri E, Torgerson TR, Ochs HD. Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. Curr Opin Rheumatol 2003; 15: 430-435.
38. Morgan ME, Van Bilsen JH, Bakker AM, Heemskerk B, Schilham MW, Hartgers FC, Elferink BG, van der Zanden L, de Vries RR. Expression of Foxp3 mRNA is not confined to CD4+CD25+ T regulatory cells in humans. Hum Immunol 2005; 66: 13-20.
39. Dumont N and Arteage CL. The tumor microenvironment: a potential activator of the tumor suppressive and promoting actions of TGF-beta. Differentiation 2002; 70: 574-82.
40. Reckamp KL, K Krysan, JD Morrow, Milne GL, Newman RA, Tucker C, Elashoff RM, Dubinett SM, Figlin RA. A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced Non-Small Cell Lung cancer. Clin. Cancer Res. 2006; 12: 3381-3388.
41. Colombo MP and Piconese S. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer 2007; 7: 880-887.
42. Wong SF and Lai LC. The role of TGF-beta in human cancer. Path 2001; 33: 85-92.
43. Moo-Young TA, Larson JW, Belt BA, Tan MC, Hawkins WG, Eberlein TJ, Goedegebuure PS, Linehan DC. Tumor-derived TGF-beta mediates conversion of CD4+Foxp3+ regulatory T cells in a murine model of pancreas cancer. J Immunother. 2009; 32: 12-21.
44. Wang MT, Honn KV, Nie D. Cyclooxygenases, prostanoids, and tumor progression. Cancer Met Rev 2007; DOI 10.1007/s10555-007-9096-5.
45. Benczik M and Gaffen SL. The interleukin (IL)-2 family cytokines: survival and proliferation signaling pathways in T lymphocytes. Immunol. Invest. 33: 109-142. 2004.
46. Bluestone JA and Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev 2003; 3: 253-257.